Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

178.70 -0.95 (-0.53%)
Streaming Delayed Price Updated: 10:42 AM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic... 
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
From iRhythm
Via GlobeNewswire
News headline image
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies ↗
 
Via Benzinga
News headline image
Earnings Preview For iRhythm Technologies ↗
 
Via Benzinga
News headline image
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
News headline image
Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock ↗
 
Via Benzinga
News headline image
Key Takeaways From iRhythm Technologies Analyst Ratings ↗
 
Via Benzinga
News headline image
Expert Ratings For iRhythm Technologies ↗
 
Via Benzinga
News headline image
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
News headline image
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? ↗
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
Topics Government
News headline image
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results ↗
 
Via Benzinga
News headline image
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says ↗
FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services. 
Via Benzinga
News headline image
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients 
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
From iRhythm
Via GlobeNewswire
News headline image
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM)... 
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Technologies Announces Results of GUARD-AF Trial
From iRhythm
Via GlobeNewswire
News headline image
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
From iRhythm
Via GlobeNewswire
News headline image
iRhythm Technologies to Participate in Upcoming Investor Conferences in September
From iRhythm
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.